OUP user menu

Journal of Crohn's and Colitis: 9 (5)


Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium


Published on behalf of

Adalimumab or infliximab for the prevention or treatment of post-operative recurrence in Crohn's disease

Takayuki Yamamoto
DOI: http://dx.doi.org/10.1016/j.crohns.2012.09.011 e157 First published online: 1 May 2013

Dear Sir,

I read with interest the article by Papamichael et al., ‘Adalimumab (ADA) for the prevention and/or treatment of post-operative recurrence of Crohn's disease (CD): a prospective, two-year, single center, pilot study’.1 In their prospective, single-center, open-label study, 23 patients who had undergone ileocecal resection for CD were treated with ADA. Eight patients received ADA therapy starting from the 14th post-operative day for the prevention of recurrence (Group I). Fifteen patients started ADA therapy when endoscopic recurrence was confirmed at 6 months post-operatively despite treatment with azathioprine (AZA), infliximab …

Log in through your institution